New Dive Co., Ltd. (CEO Cho Seong-ja) participated in the ‘6 International Advanced Medical Equipment and Medical Industry Exhibition (KOAMEX 30)’ held at EXCO in Daegu for three days from June 7 (Fri) to July 2 (Sun).
NEUDIVE takes its name from the word Neurodiversity. The discourse of diversity refers to social attempts to prohibit discrimination and prejudice based on difference and to grant the will to connect aspects of conflict and division into understanding and harmony. is to do
Diversity discourse is applied to help embrace and new understanding in areas where social prejudice exists or conflicts such as gender, cultural diversity, sexual orientation, and disability are intensifying. New Dive started from the perspective of looking at neurodiversity caused by differences in cranial nerves as a diverse ability rather than a disability.
If neurodiversity is recognized, people who have been classified as diseases or disabilities such as autism, intellectual disability, ADHD, learning disabilities, and social communication disorders can be accepted as neurodiverse people with differences in neurotransmitters and neural circuits. do. And if we provide optimized education and solutions so that they can overcome and adapt to differences on their own, they will be able to establish themselves as members of the social community.
New Dive is implementing innovative solutions for neurodiverse people digitally, with the participation of neurodiverse individuals and their families, as well as on-site medical personnel, developmental rehabilitation service experts, special education experts, and artificial intelligence experts. We develop customer-oriented solutions.
Digital solutions can be largely divided into digital care platforms that help patients and therapists communicate, and digital treatment devices that correspond to medical devices. Digital therapeutic devices refer to software medical devices that provide ‘therapeutic intervention’ to prevent, manage, and treat diseases based on medical evidence, and must be developed in accordance with the approval and approval procedures of the Ministry of Food and Drug Safety.
New Dive introduced ‘Buddyin’, a mobile digital social therapy device, at this exhibition. This program reflected the opinions of experts such as therapists and special education teachers as well as the opinions of various users such as parents and concerned persons. We collected the necessary actual situations as much as possible and applied them to product development.
As the CEO of New Dive is a doctor and has served as the head of the medical department of global pharmaceutical companies such as Janssen, Pfizer, and Lilly, he is developing a reliable digital treatment device with experts in each field based on numerous research results and papers. .
It has already been recognized as a product in the medical device field by the Ministry of Food and Drug Safety, and was also selected as a target product for the approval helper system in which the Ministry of Food and Drug Safety selects and supports newly developed medical devices. However, in order to be recognized as a treatment device rather than a wellness (personal health care) product, it must go through various processes including clinical trials over a long period of time.
CEO Seongja Cho chose a difficult and arduous path despite recommendations from people around him to release New Dive’s solution as a simple educational program or a functional game. She had responsibilities as a doctor, but also as a mother of a child on the autism spectrum.
According to the meta-analysis of the research results so far, in the case of the autism spectrum, face-to-face counseling in groups is the most effective method, followed by the use of digital treatment devices. Digital treatment devices produced more effective results than face-to-face counseling.
New Dive plans to start the first clinical trial this year and conduct a definitive clinical trial for approval next year. And through this, it aims to introduce digital treatment devices to the market after completing all the processes by 1.
In the case of neurodiverse people, even simple hospital expenses are a considerable burden. CEO Seongja of New Dive said, “Even if our solution cannot completely replace the hospital or medicine itself, we will be able to save significant costs by enabling remote medical treatment at home in addition to the digital treatment device solution.”
Meanwhile, the main exhibition items of ‘KOAMEX 2023’ hosted by Daegu Metropolitan City and K-MEDI Hub are as follows. △Diagnostic and diagnostic devices such as scanners, measuring devices, and imaging devices △Clinical and inspection devices △Surgical and recycling devices △Hospital facilities and emergency equipment △Medical devices, parts, and services △Pharmaceutical devices △Medical services, SW